Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.

The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.

Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far. 

Aortic valve replacement is likely inevitable for patients with asymptomatic severe aortic stenosis. Immediately performing TAVR or SAVR, however, may not always be the answer.

"We wanted to ensure that every interventionalist, regardless of location or resources, has access to the best information possible," one co-author said. 

Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.

Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

The country’s two biggest TAVR vendors both plan on making a splash at ACC.25. Medtronic and Edwards Lifesciences spoke to Cardiovascular Business about their plans for the three-day event in Chicago.